Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
BAKER v. TEVA PHARMACEUTICAL INDUSTRIES LTD. et al
Case Number:
2:17-cv-03902
Court:
Nature of Suit:
Other Statutes: Securities/Commodities
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
April 11, 2018
Teva Investor Suit Over $40.5B Merger Sent To Conn.
A Pennsylvania federal judge on Tuesday transferred to Connecticut two proposed investor class actions against Teva Pharmaceutical Industries Ltd. claiming the company hid the negative fallout from its $40.5 billion acquisition of Actavis Generics, ruling that the cases were substantially similar to other class actions already consolidated there.
-
August 30, 2017
Teva Hit With Investor Suit Over $40.5B Actavis Merger
A proposed class of investors in Teva Pharmaceutical Industries Ltd. slapped the drugmaker and several of its current and former executives with a suit in Pennsylvania federal court on Wednesday accusing them of concealing the negative fallout from Teva’s $40.5 billion acquisition of Actavis Generics.